The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect
Open accessAbstract
In the present study, we found that CBD inhibited U87-MG and T98G cell proliferation and invasiveness in vitro and caused a decrease in the expression of a set of proteins specifically involved in growth, invasion and angiogenesis. In addition, CBD treatment caused a dose-related down-regulation of ERK and Akt prosurvival signaling pathways in U87-MG and T98G cells and decreased hypoxia inducible factor HIF-1α expression in U87-MG cells. Taken together, these results provide new insights into the antitumor action of CBD, showing that this cannabinoid affects multiple tumoral features and molecular pathways. As CBD is a non-psychoactive phytocannabinoid that appears to be devoid of side effects, our results support its exploitation as an effective anti-cancer drug in the management of gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CBD can modulate intracellular pathways directly connected with synaptic remodeling, such as Erk1/2 and Akt, in distinct types of cancer cell lines (109, 110).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“HIF-1a is one of the major factors responsible for orchestrating the adaptive transcriptional programs, inducing cell survival, motility and tumor angiogenesis under hypoxic conditions [6,43].”
BackgroundMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/bj3510289 · Cited by 1,443
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315
Matrix metalloproteinases: they're not just for matrix anymore!
McCawley, L. J., & Matrisian, L. M. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00248-9 · Cited by 1,274
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Ten years of protein kinase B signalling: a hard Akt to follow
Brazil, D. P., & Hemmings, B. A. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01958-2 · Cited by 1,177
MAP kinases and cell migration
Huang, C., Jacobson, K., & Schaller, M. D. (2004) · Journal of Cell Science · doi:10.1242/jcs.01481 · Cited by 1,089
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. A., & Fuller, G. N. (2000) · Nature Genetics · doi:10.1038/75596 · Cited by 906
Molecular mechanisms of glioma invasiveness: the role of proteases
Rao, J. S. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1121 · Cited by 847
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–160 of 160
Cannabidiol and Cancer — An Overview of the Preclinical Data
Solinas, M., Cinquina, V., & Parolaro, D. (2015) · InTech eBooks · doi:10.5772/59193 · Cited by 9
Giannotti, L., Stanca, B. D. C., Spedicato, F., Vergara, D., Stanca, E., Damiano, F., & Siculella, L. (2024) · Antioxidants · doi:10.3390/antiox14010018 · Cited by 8
Bakshi, H. A., Hakkim, F. L., Ravesh, Z., Ansari, P., Hannan, J. M. A., Hashimoto, R., Takayama, K., Farzand, R., Nasef, M. M., Mensah, A., et al. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354221096766 · Cited by 8
Lamtha, T., Jongkon, N., Lertvanithphol, T., Horprathum, M., Seetaha, S., & Choowongkomon, K. (2025) · ACS Omega · doi:10.1021/acsomega.4c11108 · Cited by 7
Liposomal Co-Delivery of Acteoside, CBD, and Naringenin: A Synergistic Strategy Against Gliomas
Szkudlarek, J., Piwowarczyk, L., Krajka‐Kuźniak, V., Majchrzak‐Celińska, A., Tomczak, S., Baranowski, M., Pietrzyk, R., Woźniak-Braszak, A., & Jelińska, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081026 · Cited by 7
Cannabis sativa in Phytotherapy: Reappraisal of Therapeutic Potential and Regulatory Aspects
Gupta, P., Singh, A., Shafi, S., Ralli, T., Pottoo, F. H., Sultana, Y., & Kohli, K. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230508142114 · Cited by 7
Borges, H. S., Gusmão, L. A., & Tedesco, A. C. (2023) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2023.103723 · Cited by 7
Could cannabinoids provide a new hope for ovarian cancer patients?
Kaur, R., & Javid, F. A. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1122 · Cited by 6
Cannabidiol as Self-Assembly Inducer for Anticancer Drug-Based Nanoparticles
Colombo, E., Coppini, D. A., Polito, L., Ciriello, U., Paladino, G., Hyeraci, M., Paolo, M. L. D., Nordio, G., Via, L. D., & Passarella, D. (2022) · Molecules · doi:10.3390/molecules28010112 · Cited by 7
Alves, P., Amaral, C., Teixeira, N. A. A., & Correia‐da‐Silva, G. (2023) · Toxicology · doi:10.1016/j.tox.2023.153614 · Cited by 7
Wittig, F., Pannenberg, L., Schwarz, R., Bekeschus, S., Ramer, R., & Hinz, B. (2023) · Cells · doi:10.3390/cells12192332 · Cited by 6
Cannabis sativa as an Herbal Ingredient: Problems and Prospects
Oriola, A. O., Kar, P., & Oyedeji, A. O. (2024) · Molecules · doi:10.3390/molecules29153605 · Cited by 6
Ahmadi, K., Asgharzadeh, F., Mohammadpour-Asl, S., Ayari, F., Rahbar, F., Motazakker, M., Roshan‐Milani, S., & Fard, A. A. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230322092046 · Cited by 6
Mangal, N., Reebye, V., Habib, N. A., & Sodergren, M. H. (2024) · Journal of Cannabis Research · doi:10.1186/s42238-024-00227-x · Cited by 6
Unlocking the potential: Cannabidiol (CBD) as a promising anti-tumor agent
Duan, S., Liu, M., An, Z., Zhong, Z., Guan, X., Liu, X., Zhang, Z., & Yang, F. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157737 · Cited by 5
Chan, H., Lin, W., Kuo, D., & Chuang, H. (2024) · Phytotherapy Research · doi:10.1002/ptr.8413 · Cited by 5
SAR study of niclosamide derivatives in the human glioblastoma U-87 MG cells
Mito, S., Cheng, B., Garcia, B. A., Gonzalez, D., Ooi, X. Y., Ruiz, T. C., Elisarraras, F. X., Tsin, A. T. C., Chew, S. A., & Arriaga, M. A. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02907-w · Cited by 5
Chantarat, N., Pe, K. C. S., Suppipat, K., Vimolmangkang, S., & Tawinwung, S. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0108 · Cited by 5
Rani, V., Pavan, S. R., & Prabhu, A. (2022) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-022-00285-3 · Cited by 5
Narrative Review: Phytocannabinoids and their Potential Use as a Phytochemotherapy
Panichayupakaranant, P. (2020) · International Journal of Pharmacognosy & Chinese Medicine · doi:10.23880/ipcm-16000209 · Cited by 4
Tahermanesh, K., Hakimpour, S., Govahi, A., Keyhanfar, F., Mehdizadehkashi, A., Chaichian, S., Shahriyaripour, R., & Ajdary, M. (2022) · BioMed Research International · doi:10.1155/2022/1111777 · Cited by 5
Szkudlarek, J., Piwowarczyk, L., & Jelińska, A. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00853 · Cited by 4
Cannabinoid signalling in glioma cells
Kaminska, B., & Ellert‐Miklaszewska, A. (2015) · SpringerPlus · doi:10.1186/2193-1801-4-s1-l11 · Cited by 4
Microbial Biotransformation of Cannabidiol (CBD) from Cannabis sativa
Ahmed, S. A., Ibrahim, A. K., Radwan, M. M., Slade, D., Chandra, S., Khan, I. A., & ElSohly, M. A. (2021) · Planta Medica · doi:10.1055/a-1468-3781 · Cited by 4
Peeri, H., & Koltai, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89862-1.00030-1 · Cited by 3
Sathynathan, C. V., Lakshmisundaram, R., Surenderan, S., Kaur, H., Dandapani, M. C., Thyagarajan, S. P., & Gnanambal, K. M. E. (2024) · Molecules · doi:10.3390/molecules29081737 · Cited by 3
Zhelyazkova, M., Hristova-Avakumova, N. G., Todorov, L. T., & Momekov, G. (2021) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2021.1996270 · Cited by 3
Zafar, R. R., Sulak, D., Brambila, J., Nutt, D., & Schlag, A. K. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221114323 · Cited by 3
Rejili, M., Farahani, N., Alimohammadi, M., & Hushmandi, K. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117781 · Cited by 3
Therapeutic role of nutraceuticals in the management of brain disorders
Benmelouka, A. Y., Shah, M. A., Saleem, U., Elshanbary, A. A., Meshref, M. M., Shah, G. M., Alsharif, I., Althobaiti, N. A., & Alhasani, R. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824356-5.00012-6 · Cited by 2
Progress on the functions and mechanisms of natural products in anti-glioma therapy
Li, Y., Qu, S., Zuo, J., Long, H., Cao, F., & Jiang, F. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60815-6 · Cited by 3
Cannabinoid Signaling in Glioma Cells and Therapeutic implications
Ellert‐Miklaszewska, A., Ciechomska, I. A., & Kaminska, B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00076-4 · Cited by 2
Praphasawat, R., Singsai, K., Muenkaew, P., Sirisawat, S., Jaewcharoenchai, W., Thakaew, S., Komkhan, S., & Rawangkarn, A. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.5.1579 · Cited by 1
Martinez, K., Palma, M. B., Sepúlveda, F. J., Moavro, D. E., Carosella, E. D., García, M. N., & Riccillo, F. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-23554-2 · Cited by 1
Cannabidiol-induced cellular and matrix-associated responses in primary equine sarcoid cells
Semik‐Gurgul, E., Oclon, E. A., Zubel–Łojek, J., Pędziwiatr, R., & Pawlina‐Tyszko, K. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalaf015 · Cited by 1
Cannabinoids as seed compounds for the cancer treatment
Yasukawa, K. (2014) · Forensic Toxicology · doi:10.1007/s11419-014-0234-9 · Cited by 1
The antitumor action of endocannabinoids in the tumor microenvironment of glioblastoma
Tang, Y., Wang, M., Yu, J.-P., Lv, G., Wang, Y., & Yu, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1395156 · Cited by 2
Triple Negative Breast Cancer (TNBC): Cannabis sativa-Role of Phytocannabinoids
Malabadi, R. B., Kolkar, K. P., Sadiya, M. R., Veena Sharada, B., Mammadova, S. S., CHALANNAVAR, R. K., Baijnath, H., Nalini, S., Nandini, S., & Munhoz, A. N. R. (2024) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2024.17.3.0113 · Cited by 6
Gurgul, A., Jasielczuk, I., Szmatoła, T., Semik‐Gurgul, E., Kucharski, M., Mizera-Szpilka, K., & Oclon, E. A. (2025) · Journal of Applied Genetics · doi:10.1007/s13353-025-00970-8 · Cited by 1
Pharmacological actions and associated therapeutic levels of phytocannabinoids Addendum 2021
Arnold, J. C., Allsop, D., Lintzeris, N., & McGregor, I. S. (2016) · doi:10.57022/ovds2305 · Cited by 1
Discovery of Novel Small Molecule CB2 Agonist for the Treatment of Glioblastoma TumorsPreprint
Király, M., Okwan-Duodu, D. K., Wong, A. J., Foss, J. F., & Giordano, T. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.16.572001 · Cited by 1
Advances in Pharmacological Research of Cannabidiol
韩, 莎. (2019) · Pharmacy Information · doi:10.12677/pi.2019.83006
Emerging treatments and therapeutic targets for tuberous sclerosis complex in children
Słowińska, M., & Jóźwiak, S. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1662295
O’Brien, K., & Blair, P. (2021) · Springer eBooks · doi:10.1007/978-3-030-78559-8_8
https://restorativemedicine.org/journal/cbd-physiological-modulator-cancer/
Miranda-Massari, J. R. (2023) · Journal of Restorative Medicine · doi:10.14200/jrm.2023.0002
Cannabis in the Treatment of Various Cancers and its Current Global Scenario
Patil, S., & Mulik, M. B. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124699123010016
Borges, H. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.59.2023.tde-04102023-132705
Cannabidiol modulates classical and non-classical HLA expression in human choriocarcinoma cell line
Martinez, K., Palma, M. B., Sepúlveda, F. J., Carosella, E. D., García, M. N., & Riccillo, F. L. (2026) · Human Immunology · doi:10.1016/j.humimm.2026.111768
Sousa, D., Amaro, F., Araújo, A. M., & Carvalho, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020792
Martinez, A. F. S., Díaz, L. E., Conde-Martínez, N., Bustos, R. H., Delgado, M. X. L., & Quintanilla‐Carvajal, M. X. (2026) · Nanomaterials · doi:10.3390/nano16080459
Creangă-Murariu, I., Rezuş, I.-I., Karami, R., Makolli, A., Chifu, C., Rancz, A., Sipos, Z., Ferdinandy, P., Papp, R., Teutsch, B., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19050768
Insight into the mode of action of phytocannabinoids against ovarian cancer and glioblastoma
Koltai, H., & Kendall, B. E. (2026) · Phytomedicine Plus · doi:10.1016/j.phyplu.2026.101012
O’Brien, K., & Blair, P. (2026) · Springer eBooks · doi:10.1007/978-3-032-14521-5_8
Guan, L., Deng, X., Zheng, J., Yang, Z., Jiang, X., & Wang, Y. (2026) · BioMed Research International · doi:10.1155/bmri/6385332
Cannabidiol alters the epigenome of hormone-dependent prostate cancer cells
Cosgrave, J. M., Magee, R., O’Reilly, E., Hughes, C., Jordan, A., Silva, R., McCabe, A., Dean, K. A., Prencipe, M., Gallagher, W. M., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119891
SLC25 in intestinal inflammation: mechanisms, pathological roles, and therapeutic implications
Xu, J., Zuo, Z., Wang, P., He, T., Xun, L., An, Y., Luo, M., Qi, J., & Wan, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1915452
Załuska-Ogryzek, K., Wróblewska-Łuczka, P., Góralczyk, A., Chojnacki, M., & Łuszczki, J. J. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00898-8
Nkune, N. W., & Abrahamse, H. (2026) · Journal of Photochemistry and Photobiology · doi:10.1016/j.jpap.2026.100319
Chhitij, T., Kim, H. J., Kim, D., Lee, S., & Chun, K. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01631-y
Metadata
- Authors
- Solinas, M., Massi, P., Cinquina, V., Valenti, M., Bolognini, D., Gariboldi, M., Monti, E., Rubino, T., & Parolaro, D.
- Affiliations
- University of Insubria (IT)
- University of Milan (IT)
- University of Toronto (CA)
- Corresponding author
- Parolaro, Daniela
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-21
- Volume
- 8
- Issue
- 10
- Pages
- e76918
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3804588
- OpenAlex
- W2083034715
- Cited by
- 159
- References
- 47
- Citations by year
- 2026: 14 · 2025: 8 · 2024: 17 · 2023: 22 · 2022: 21 · 2021: 24 · 2020: 14 · 2019: 10 · 2018: 9 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 3
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IrInSubria (University of Insubria) (submittedVersion)
- Funders
- Università degli Studi di Milano
- GW Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- cannabidiol, glioma, U87 cells, T98G cells, cell proliferation, tumor invasion, angiogenesis, ERK signaling, Akt signaling, HIF-1α, anticancer activity, phytocannabinoids
- MeSH terms
- Antineoplastic Agents, Cannabidiol, Cell Movement, Cell Survival, Dose-Response Relationship, Drug, Glioma, Humans, Neoplasm Invasiveness, Blotting, Western, Signal Transduction, Proteome, Proteomics, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Proto-Oncogene Proteins c-akt, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
